Formosa Laboratories, Inc. (4746.TW)
TWD 71.9
(-0.96%)
TWD 71.9
(-0.96%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.53 Billion TWD | 0.67% |
| 2022 | 2.52 Billion TWD | -6.35% |
| 2021 | 2.69 Billion TWD | 4.26% |
| 2020 | 2.58 Billion TWD | -19.23% |
| 2019 | 3.19 Billion TWD | 52.9% |
| 2018 | 2.09 Billion TWD | 284.77% |
| 2017 | 543.44 Million TWD | -24.87% |
| 2016 | 723.36 Million TWD | -51.9% |
| 2015 | 1.5 Billion TWD | 5.09% |
| 2014 | 1.43 Billion TWD | 15.5% |
| 2013 | 1.23 Billion TWD | -23.78% |
| 2012 | 1.62 Billion TWD | 134.87% |
| 2011 | 692.11 Million TWD | 33.45% |
| 2010 | 518.63 Million TWD | 0.0% |
| 2009 | - TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 2.81 Billion TWD | 14.86% |
| 2024 Q1 | 2.45 Billion TWD | -3.42% |
| 2023 FY | 2.53 Billion TWD | 0.67% |
| 2023 Q4 | 2.53 Billion TWD | -5.85% |
| 2023 Q3 | 2.69 Billion TWD | 34.91% |
| 2023 Q2 | 1.99 Billion TWD | -15.32% |
| 2023 Q1 | 2.35 Billion TWD | -6.41% |
| 2022 Q1 | 2.75 Billion TWD | 2.23% |
| 2022 Q4 | 2.52 Billion TWD | -5.75% |
| 2022 Q2 | 2.65 Billion TWD | -3.47% |
| 2022 FY | 2.52 Billion TWD | -6.35% |
| 2022 Q3 | 2.67 Billion TWD | 0.68% |
| 2021 Q1 | 2.15 Billion TWD | -16.5% |
| 2021 Q2 | 2.38 Billion TWD | 10.55% |
| 2021 FY | 2.69 Billion TWD | 4.26% |
| 2021 Q3 | 2.37 Billion TWD | -0.4% |
| 2021 Q4 | 2.69 Billion TWD | 13.4% |
| 2020 FY | 2.58 Billion TWD | -19.23% |
| 2020 Q1 | 2.87 Billion TWD | -10.17% |
| 2020 Q3 | 2.09 Billion TWD | -33.32% |
| 2020 Q4 | 2.58 Billion TWD | 23.51% |
| 2020 Q2 | 3.13 Billion TWD | 9.19% |
| 2019 FY | 3.19 Billion TWD | 52.9% |
| 2019 Q4 | 3.19 Billion TWD | 6.15% |
| 2019 Q3 | 3.01 Billion TWD | 7.5% |
| 2019 Q2 | 2.8 Billion TWD | 7.47% |
| 2019 Q1 | 2.6 Billion TWD | 24.67% |
| 2018 Q3 | 1.87 Billion TWD | 15.22% |
| 2018 Q2 | 1.62 Billion TWD | 42.57% |
| 2018 Q1 | 1.14 Billion TWD | 110.16% |
| 2018 FY | 2.09 Billion TWD | 284.77% |
| 2018 Q4 | 2.09 Billion TWD | 11.45% |
| 2017 Q1 | 686.31 Million TWD | -5.12% |
| 2017 Q4 | 543.44 Million TWD | -31.98% |
| 2017 Q3 | 798.9 Million TWD | 11.42% |
| 2017 Q2 | 717.03 Million TWD | 4.47% |
| 2017 FY | 543.44 Million TWD | -24.87% |
| 2016 Q1 | 1.55 Billion TWD | 3.23% |
| 2016 Q4 | 723.36 Million TWD | -6.32% |
| 2016 Q2 | 1.42 Billion TWD | -8.07% |
| 2016 FY | 723.36 Million TWD | -51.9% |
| 2016 Q3 | 772.15 Million TWD | -45.9% |
| 2015 Q3 | 1.6 Billion TWD | 4.77% |
| 2015 FY | 1.5 Billion TWD | 5.09% |
| 2015 Q4 | 1.5 Billion TWD | -6.22% |
| 2015 Q2 | 1.53 Billion TWD | 9.58% |
| 2015 Q1 | 1.39 Billion TWD | -2.38% |
| 2014 Q2 | 1.4 Billion TWD | 3.91% |
| 2014 Q1 | 1.35 Billion TWD | 9.47% |
| 2014 Q4 | 1.43 Billion TWD | 5.81% |
| 2014 FY | 1.43 Billion TWD | 15.5% |
| 2014 Q3 | 1.35 Billion TWD | -4.03% |
| 2013 Q1 | 1.53 Billion TWD | -5.4% |
| 2013 Q2 | 2.14 Billion TWD | 39.76% |
| 2013 Q3 | 1.41 Billion TWD | -34.27% |
| 2013 Q4 | 1.23 Billion TWD | -12.29% |
| 2013 FY | 1.23 Billion TWD | -23.78% |
| 2012 Q4 | 1.62 Billion TWD | 28.57% |
| 2012 Q1 | 761.67 Million TWD | 10.05% |
| 2012 Q2 | 962.14 Million TWD | 26.32% |
| 2012 FY | 1.62 Billion TWD | 134.87% |
| 2012 Q3 | 1.26 Billion TWD | 31.41% |
| 2011 Q3 | 662.49 Million TWD | 215.05% |
| 2011 Q4 | 692.11 Million TWD | 4.47% |
| 2011 Q1 | 65.52 Million TWD | -87.37% |
| 2011 Q2 | 210.28 Million TWD | 220.91% |
| 2011 FY | 692.11 Million TWD | 33.45% |
| 2010 FY | 518.63 Million TWD | 0.0% |
| 2010 Q4 | 518.63 Million TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Grape King Bio Ltd | -4.62 Billion TWD | 154.875% |
| Standard Chem & Pharm CO., LTD. | -954.74 Million TWD | 365.872% |
| Maywufa Company Ltd. | 264.18 Million TWD | -860.839% |
| ScinoPharm Taiwan, Ltd. | -3.32 Billion TWD | 176.448% |
| Lotus Pharmaceutical Co., Ltd. | 9.81 Billion TWD | 74.135% |
| LIWANLI Innovation Co., Ltd. | -244.02 Million TWD | 1140.227% |
| YungShin Global Holding Corporation | -247.5 Million TWD | 1125.609% |
| PhytoHealth Corporation | -34.64 Million TWD | 7427.713% |
| SCI Pharmtech, Inc. | 100.41 Million TWD | -2427.852% |
| PharmaEssentia Corporation | -18.46 Billion TWD | 113.746% |
| Bora Pharmaceuticals Co., LTD. | 1.95 Billion TWD | -29.738% |